Summary Overexpression of cyclin Dl is frequently found in various types of human tumours and results from clonal rearrangement and/or amplification involving chromosomal region 1 1q13. In order to evaluate the pathological relevance of cyclin DI overexpression in human breast cancer, we generated a polyclonal antiserum against the carboxy-terminal part of the cyclin DI protein. After affinity purification, the antiserum specifically detected overexpression of cyclin DI in formalin-fixed, paraffin-embedded tumour material also. The intensity of the nuclear stainings was, in generai, proportional to the degree of cyclin DI amplification. We did not encounter significant variability of staining within individual tumours with overexpression of cyclin Dl. Overexpression of cyclin DI appeared to be associated with oestrogen receptor-positive breast tumours, but not with any other clinicopathological parameter tested. Overexpression of cyclin Dl was not of prognostic value for recurrence or survival in a consecutive series of 248 operable breast cancer patients (stage I and II). Overexpression of p53 was also not of prognostic significance in this series, but was associated with undifferentiated histology and oestrogen receptor-negative breast tumours, as has been reported previously by others. A high proportion of breast tumours with a low grade of malignancy in this series of operable breast cancer patients may explain discrepancies concerning the prognostic value of amplification and of overexpression of cyclin Dl.
Molecular biological research over the past several years has led to the identification of alterations in many different protooncogenes and tumour-suppressor genes, which in various combinations contribute to the development of tumours (Bishop, 1987) . Most of these studies have attempted to relate genetic alterations with clinical parameters. Mutation of p53, for instance, is more frequent in the more advanced stages of colon cancer than in early lesions, suggesting a late role in tumour progression (Vogelstein et al., 1988) . The transitions from benign to malignant phenotype are clearly recognisable in colon cancer, where adenomas represent the benign lesion, from which invasive carcinomas develop via increasing degrees of dysplasia (Sugarbaker et al., 1985) . Such clear transition stages cannot be distinguished in breast tumours. Moreover, breast cancers are a heterogeneous group of diseases, both in morphology and in behaviour. Therefore, molecular biological studies in breast cancer have to rely on prognosis, associating genetic changes with follow-up (disease-free survival period), using long-term follow-up and large patient series to overcome heterogeneity effects. To evaluate such an association in breast cancer, we investigated a series of 248 consecutive patients treated in our clinic for operable breast cancer between 1979 and 1982. We followed these patients for an average period of 10 years and investigated associations of disease-free interval and clinicopathological parameters, among which overexpression of cyclin Dl and p53. Overexpression of cyclin Dl was previously found to be associated with poor prognosis (Borg et al., 1991; Henry et al., 1993; Schuuring et al., 1992a; Tsuda et al., 1989) . Rearrangements involving cyclin Dl were found in many different tumour types, such as carcinomas of the breast, oesophagus, stomach, bladder and liver, and in squamous carcinomas of the head and neck (for reviews, see Lammie and Peters, 1991; Motokura and Arnold, 1993) . Deregulation of other cyclins has also been detected in tumours, but deregulation of cyclin Dl appeared to be of singular importance in the multistep process of oncogenesis (Keyomarsi and Pardee, 1993) .
In normal cells, cyclin Dl protein forms a multimer complex with cyclin-dependent kinase, which regulates transition through the GI phase of the cell cycle (Sherr, 1993) . Overexpression of cyclin Dl either by transfection of cyclin Dl in fibroblast cells, or in target tissues of cyclin Dltransgenic mice, resulted in transformation only in conjunction with other activated oncogenes, such as EIA, myc or ras. This suggests a cooperativity in transformation between overexpression of cyclin Dl and other oncogenes (Bodrug et al., 1994; Hinds et al., 1994; Wang et al., 1994) . Overexpression of cyclin DI rendered growth of normal cells less dependent on growth factors, and shortened the GI phase of the cell cycle (Quelle et al., 1993) .
The other oncogene alteration examined in this study is alteration of the p53 tumour-suppressor gene, which occurs in about 60% of human cancers. In combination with a reduction in homozygosity this results in the complete loss of the wild-type allele (Harris and Holstein, 1993; Levine et al., 1994) . The majority of p53 mutations found in human tumours are missense mutations, usually altering protein conformation and causing nuclear accumulation of p53, which can be demonstrated by immunohistochemistry (Harris and Holstein, 1993) . Mutation of p53 appears to be associated with a more undifferentiated phenotype (Marchetti et al., 1993) , is maintained throughout breast cancer progression (Davidoff et al., 1991) and has been found as an independent prognostic marker in a group of lymph nodenegative breast cancer patients (Silvestrini et al., 1993; Thor et al., 1992) .
Thus far, immunohistological evaluation of overexpression of cyclin Dl in retrospective series has been hampered by lack of antibodies detecting cyclin Dl in formalin-fixed, paraffin-embedded tumour tissue. We affinity purified a rabbit antiserum directed against human cyclin Dl, which detects overexpression of cyclin Dl in formalin-fixed, paraffin-embedded breast tumours. This antiserum was used in a retrospective study of 248 breast cancer patients. Tissues were fixed for at least 24 h in neutral buffered 4% formaldehyde. After paraffin embedding, 5-um-thick sections were cut and routinely stained with haemotoxylin and eosin. All slides were reviewed by one pathologist (JP), tumours were typed according to WHO (1981) criteria and invasive ductal carcinomas were graded according to a modification of Bloom and Richardson's method (Elston and Ellis, 1990 
Immunohistochemistry
The primary antibodies used for staining of sections were an affinity-purified rabbit anti-cyclin Dl antibody (Michalides et al., 1995) and a mouse monoclonal antibody detecting p53, DO-7 (Dako). The affinity-purified rabbit polyclonal antibody was generated by injection of a P-galactosidase-cyclin Dl fusion protein, using the carboxy-terminal part of cyclin Dl (aa 217-296, corresponding with the NcoI-DdeI fragment of cyclin Dl) into rabbits. Antibodies directed against the cyclin Dl part of the fusion protein were affinity purified on a GST-cyclin-Di fusion protein, using the whole size cyclin Dl protein (corresponding with the NcoI-HindIII fragment of cyclin Dl), coupled covalently to a CH-activated Sepharose-4B (Pharmacia). With this procedure, antibodies reactive to the P-galactosidase and (contaminating) bacterial proteins were removed. In immunoprecipitation experiments, the antibody was shown to be specific for cyclin DI (Michalides et al., 1995) , and did not cross-react with either cyclin D2 or cyclin D3, since no immunostaining was found with H9 cells, which express these members of the cyclin D family, but not cyclin Dl .
For immunohistochemistry, dewaxed and rehydrated sections (on silane-coated slides) were covered with citrate buffer (10 mM, pH 6) and underwent a microwave-retrieval treatment (setting at 450 W) for 15 min (Greenwell et al., 1991) . The slides were then washed twice with phosphatebuffered saline (PBS), and were rinsed thoroughly with PBS between each of the following steps. The sections were first blocked with undiluted swine serum (for staining of cyclin DI) or rabbit serum (for staining of p53), for 10 min at 37°C. The sections were then incubated overnight with a 1: 80 dilution of B31S affinity-purified rabbit-anti-cyclin Dl in PBS/i % bovine serum albumin (BSA), or with a 1:400 dilution of DO-7 overnight at 4°C. Sections were then incubated with biotinylated rabbit anti-mouse, or swine antirabbit antiserum (1:1000 in PBS/I %BSA) (Dako) for 30 min at room temperature. Preformed peroxidase-conjugated streptavidin -biotin complex (Dako) was then applied for 30 min at room temperature, and peroxidase was demonstrated by applying 0.05% diaminobenzidine containing 0.6% hydrogen peroxide for 5 min. The samples were then thoroughly washed in water, nuclei were lightly counterstained with haematoxylin, and sections were dehydrated and mounted. For each of the antibodies, a corresponding tissue section was incubated in PBS without the primary antibody as a control for non-specific staining.
Statistical analyses
Associations between overexpression of cyclin DI or p53 and clinicopathological variables were analysed using the chisquare test or the Fisher test for discrete variables and the ttest for continuous variables. Survival curves and disease-free interval curves were calculated using the method of Kaplan and Meier (1958) . The statistical analyses of the differences between the curves were performed using the stratified logrank test for censored data, with time to recurrence or death as end points (Mantel, 1966 Frye et al. (1989) , using cyclin Dl primer combinations: 5'-GAAAGTAGGACCTCA-3', (nt 2335-2350) and 5'-CCTGTCCTCCCT-3' (nt 2912-2901), yielding a cyclin Dl DNA fragment of 577 nucleotides, and as control PBGD (phorbobilinogen deaminase) primers 5'-ATGA-GAGTGATTCGCGTGGGT-3' and 5'-TTTCAATGTTGC-CACCACACT-3' (corresponding to cDNA positions 79-98 and 131-1 56 respectively), yielding a genomic PBGD fragment of 430 nucleotides. Polymer chain reaction (PCR) conditions were as follows: denaturation of the DNA at 94°C for 1 min, annealing at 63°C for 30 s and transcription at 72°C for 2 min. PCR was performed using 2 mm magnesium chloride for 24 cycles using 1 pCi of [X_-32P]dCTP (3000 Ci mmol-', Amersham) using increasing amounts of cellular DNA. The 32P-labelled PCR-DNA products were analysed on a 6% polyacrylamide gel. The gels were fixed in 10% acetic acid, dried and exposed on Kodak X-ray films at -70°C using intensifying screens. Quantitation of autoradiograms was performed by image analysis using a Cohu camera (type 4712 with a 50 mm Nikkon lens) and the public domain program NIH Image (Wayne, NIH), run on an Apple Macintosh LCII. The ratio of intensities of the PCR-DNA fragments of cyclin Dl and PBGD at non-saturating levels of input cellular DNA was determined to indicate the degree of cyclin Dl amplification.
Results
Immunohistochemical detection of overexpression of cyclin DI The affinity-purified polyclonal antibody against cyclin DI, B31S, detected a 33 kDa cyclin DI protein in immunoprecipitation experiments using cyclin DI-expressing cells (Michalides et al., 1995) . This antibody detected nuclear staining of cyclin Dl in cyclin Dl-overexpressing cells, such as MCF-7 and UMSCC2. This reactivity was removed after preabsorption of the antibody with an excess of in vitrogenerated GST-cyclin Dl protein. Dl (Lukas et al., 1994) . Despite this variation, straightforward gradation of the staining, depending on staining intensity and percentage of nuclei staining could easily be performed by three independent observers, + +, > 50% of the nuclei positive with a strong intensity; +, 5-50% of the tumour nuclei clearly positive; +/-less than 5% of the tumour nuclei positive with weak intensity; and -, negative, no staining at all. Examples of staining results are given in Figure 1 . Similar staining patterns have been reported in methacarn-fixed tumours by others (Bartkova et al., 1994; Gillett et al., 1994) , using the monoclonal antibody DCS-6.
In order to correlate the immunohistochemical overexpression of cyclin Dl with the degree of amplification, we examined various breast tumours for cyclin Dl staining as well as cyclin Dl amplification. The range of amplification of the cyclin Dl gene varied from 1 to 10 in the 12 breast tumour samples analysed, see Table I . With one exception, tumour sample 436T, the immunohistological staining of the corresponding tumour preparations, fixed in formalin and embedded in paraffin, correlated with the degree of amplification of cyclin Dl DNA. The one exception, 436T, was previously shown to contain an overexpression of cyclin Dl mRNA without concomitant cyclin Dl amplification (Schuuring et al., 1992b) . These results indicate that, in these tumours, immunohistological staining of cyclin DI with antiserum B3 1S corresponds to amplification. We stress, however, that amplification levels as determined with quantitative PCR, are not absolute, because of the admixture of normal cells.
Immunohistochemical detection of p53 Immunohistochemical detection of p53 was performed in a similar way to cyclin Dl, but using monoclonal antibody DO-7 (Ebina et al., 1994) . Only clear nuclear staining of p53 was accounted for in this series. The grading of p53 staining of the tumours was identical to the grading used for the cyclin DI staining. This grading system has also been used with this antiserum by others (Cornelis et al., 1994; Ebina et al., 1994) , and demonstrated a correlation between p53 mutation and nuclear overexpression of p53 (Cornelis et al., 1994 ). An example of a + + staining of p53 is given in Figure 1 .
Association of overexpression of cyclin DI or p53 with clinicopathological parameters Overexpression of cyclin Dl occurred in 85/248 (= 34%), and of p53 in 44/248 (= 18%) of the breast cancer cases. (Figure 2 and Table III) .
Subgroup analysis of overexpression of either cyclin Dl or p53 and disease-free interval in ER-positive and ER-negative breast cancer patients revealed an opposite trend (Table IV) . In the ER-negative subgroup, the association between overexpression of cyclin DI and disease-free interval reached statistical significance (P= 0.02). This is, however, based on small numbers (four out of six patients with overexpression of cyclin DI showed recurrence, whereas only 16 out of 58 cyclin DI-negative cases did so). There was no association between overexpression of cyclin Dl or p53 and disease-free interval in either the lymph node-negative or lymph nodepositive subgroup.
The characteristic clinicopathological parameters for breast cancer, such as number of positive lymph nodes, age of the patients, tumour grade and pathological T and N status, appeared to be significant prognostic marker for disease-free interval and mortality in this group of breast cases (Table III (1994) . We also found a significant association between overexpression of cyclin DI and ER positivity of breast tumours (Borg et al., 1991; Schuuring et al., 1992a; Henry et al., 1993) . A difference, however, was found with respect to the prognostic value of cyclin Dl. Previous studies indicated Oierexpression of p53 Overexpression of p53 was included in this study for comparison of our series of patients with others. Positive immunohistochemical staining of p53 is generally accepted to reflect the presence of mutated p53 Hollstein. 1993: Levine et al.. 1994) . because many mutant proteins have greatly expanded half-lives. Immunohistochemical detection of overexpression of p53. using monoclonal antibody. DO-7 and evaluating only nuclear staining pattern, correlated significantly with mutation in the p53 gene (Cornelis et al.. 1994 : Ebina et al.. 1994 . Using strict criteria. we found 180o of the 248 breast tumour cases to be positive. which is within the range reported by others (Cornelis et al.. 1994 : Thor et al.. 1992 . The statistically significant associations between p53 overexpression and clinical parameters such as tumour size. histological grade.
and ER negativitv. were also found by others (Faille et al.. 1994 : Marchetti et al.. 1993 Thor et al.. 1992) . By these criteria. our series does not deviate from other tumour series. No association was found with disease-free interval. also not in the ER-negative or lymph node-negative or -positive subgroups of these 248 breast tumours cases. In this aspect. our series differs from others. in which such an association was found (Silvestrini et al.. 1993 : Thor et al.. 1992 . In those studies. overexpression of p53 occurred more frequently in tumours with clinical metastases at time of presentation. Since patients with clinical metastases are not included at all in our study. we argue that p53 overexpression is not indicative of prognosis in the group of breast cancer cases that entered this study. i.e. a group selected only for surgical resection. without distant metastasis and with relatively small tumour size.
Overexpression of p53 occurs in the earliest recognised phase of breast cancer. is maintained during breast tumour progression (Davidoff et al.. 1991 ) and appears to be associated with large tumours and with metastases at time of presentation (Faille et al.. 1994 : Thor et al.. 1992 ). Since such tumours were not included in our study. this would support the notion that p53 overexpression could be a marker for prognosis when no selection of patients is applied at all. but would remain unnoticed in a selected group of patients still eligible for adjuvant therapy. This could also apply for overexpression of cyclin Dl.
